Phase 1 Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Oral Doses of DS-2969b, a Novel GyrB Inhibitor, in Healthy Subjects

DS-2969b is a novel GyrB inhibitor in development for the treatment of Clostridium difficile infection (CDI). The aim of this study was to assess the safety, tolerability, pharmacokinetics, and effects on the normal gastrointestinal microbiota of multiple daily oral ascending doses of DS-2969b in he...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Antimicrob Agents Chemother
Main Authors: Vandell, Alexander G., Inoue, Satoshi, Dennie, Justin, Nagasawa, Yasuo, Gajee, Roohi, Pav, Joe, Zhang, George, Zamora, Cynthia, Masuda, Nobuhisa, Senaldi, Giorgio
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2018
Assuntos:
Experimental Therapeutics
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5923173/
https://ncbi.nlm.nih.gov/pubmed/29439973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.02537-17
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados